{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:12:10Z","timestamp":1778749930565,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.prp.2024.155787","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T13:32:04Z","timestamp":1734701524000},"page":"155787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression"],"prefix":"10.1016","volume":"266","author":[{"given":"Katharina","family":"Bischof","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arild","family":"Holth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assia","family":"Bassarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2024.155787_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.prp.2024.155787_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.prp.2024.155787_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.annonc.2021.12.007","article-title":"European cancer mortality predictions for the year 2022 with focus on ovarian cancer","volume":"33","author":"Dalmartello","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2024.155787_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"8","key":"10.1016\/j.prp.2024.155787_bib5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.prp.2024.155787_bib6","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/0008-5472.CAN-21-3819","article-title":"Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.prp.2024.155787_bib7","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1038\/s41467-020-18819-5","article-title":"Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome","volume":"11","author":"Hollis","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.prp.2024.155787_bib8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"6001","key":"10.1016\/j.prp.2024.155787_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.prp.2024.155787_bib10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2024.155787_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2017.06.008","article-title":"Impact of ascites volume on clinical outcomes in ovarian cancer: a cohort study","volume":"146","author":"Szender","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2024.155787_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2019-000310","article-title":"Correlation of differential ascites volume with primary cytoreductive surgery outcome, lymph node involvement, and disease recurrence in advanced ovarian cancer","author":"Lai","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2024.155787_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.prp.2024.155787_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PGP.0000000000000864","article-title":"PRAME expression in endometrioid and serous endometrial carcinoma: a potential immunotherapeutic target and possible diagnostic pitfall","volume":"42","author":"Coppock","year":"2023","journal-title":"Int J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2024.155787_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/PGP.0000000000000959","article-title":"PReferentially expressed antigen in MElanoma expression in uterine and ovarian carcinosarcomas","volume":"43","author":"Alrohaibani","year":"2024","journal-title":"Int J. Gynecol. Pathol."},{"issue":"6","key":"10.1016\/j.prp.2024.155787_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061801","article-title":"PRAME promotes cervical cancer proliferation and migration via wnt\/beta-catenin pathway regulation","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.prp.2024.155787_bib17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME expression in cancer. a systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"issue":"29","key":"10.1016\/j.prp.2024.155787_bib18","doi-asserted-by":"crossref","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.prp.2024.155787_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1309\/AJCPGA95KVSAUDMF","article-title":"PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma","volume":"137","author":"Brenne","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2024.155787_bib20","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10585-023-10251-5","article-title":"Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance","volume":"41","author":"Dos Santos","year":"2024","journal-title":"Clin. Exp. Metastas."},{"key":"10.1016\/j.prp.2024.155787_bib21","series-title":"Serous Effusions Etiology, Diagnosis, Prognosis and Therapy","year":"2018"},{"issue":"5","key":"10.1016\/j.prp.2024.155787_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.humpath.2007.10.002","article-title":"Claudin upregulation in ovarian carcinoma effusions is associated with poor survival","volume":"39","author":"Kleinberg","year":"2008","journal-title":"Hum. Pathol."},{"issue":"9","key":"10.1016\/j.prp.2024.155787_bib23","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/ijc.23758","article-title":"Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas","volume":"123","author":"Partheen","year":"2008","journal-title":"Int J. Cancer"},{"issue":"16","key":"10.1016\/j.prp.2024.155787_bib24","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.ejca.2006.06.026","article-title":"Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors","volume":"42","author":"Partheen","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2024.155787_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12967-018-1757-3","article-title":"PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer","volume":"17","author":"Al-Khadairi","year":"2019","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.prp.2024.155787_bib26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1535-7163.MCT-21-0827","article-title":"Loss of claudin-4 reduces DNA damage repair and increases sensitivity to PARP inhibitors","volume":"21","author":"Yamamoto","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.prp.2024.155787_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00428-023-03567-w","article-title":"Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma","volume":"484","author":"Davidson","year":"2024","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.prp.2024.155787_bib28","first-page":"566","article-title":"Profiling of cytokines in human epithelial ovarian cancer ascites","volume":"2","author":"Matte","year":"2012","journal-title":"Am. J. Cancer Res"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824006988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824006988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:30:09Z","timestamp":1778747409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824006988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"alternative-id":["S0344033824006988"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155787","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155787"}}